Eliquis vs Xarelto vs Pradaxa: DOAC Cost Comparison for 2026

Eliquis (apixaban), Xarelto (rivaroxaban), and Pradaxa (dabigatran) are the three original direct oral anticoagulants (DOACs) approved to reduce stroke risk in atrial fibrillation and to treat or prevent deep vein thrombosis (DVT) and pulmonary embolism (PE). A fourth DOAC, Savaysa (edoxaban), holds a much smaller share of the US market and is not covered in depth on this page. Eliquis and Xarelto both block factor Xa in the clotting cascade, while Pradaxa directly inhibits thrombin. That mechanism difference does not change how each drug is billed, but the three drugs have sharply different generic status, IRA negotiation status, and manufacturer assistance programs in 2026, which is why comparing them side by side matters more for your wallet than the clinical mechanism does. For single-drug detail, see the dedicated pages for Eliquis cost and Xarelto cost.

The Inflation Reduction Act of 2022, signed August 16, 2022, authorized CMS to negotiate Medicare drug prices directly with manufacturers for the first time. Eliquis and Xarelto were both among the first 10 drugs selected for Round 1 negotiation, and their Maximum Fair Prices of $231 and $197 per month took effect January 1, 2026. Pradaxa was excluded from that selection process entirely because a generic version of dabigatran had already launched in 2022, and the statute bars CMS from selecting drugs that already face generic or biosimilar competition. That single distinction is the biggest driver of the 2026 cost gap between Pradaxa and its two brand-protected competitors, and it means Pradaxa patients should focus on generic substitution rather than waiting for a negotiated Medicare price that will never arrive for this drug.

Patients switching between these three DOACs for cost reasons should talk to their prescriber first. Eliquis, Xarelto, and Pradaxa have different dosing schedules, different renal-function adjustment rules, and different reversal agents in an emergency (Pradaxa uses idarucizumab; Eliquis and Xarelto use andexanet alfa). None of the three is a biologic, so no biosimilar exists or is expected for any of them; the biosimilar approval pathway only applies to large-molecule drugs, not these small-molecule anticoagulants. The comparison table below lays out cash price, Medicare Part D treatment, generic availability, and manufacturer patient assistance program for all three drugs side by side.

What DOAC Comparison Costs by Point of Pay (2026)

The price you pay depends almost entirely on WHERE you pay. The same doac comparison can cost many times more at a hospital than at your local pharmacy:

Why Hospitals Charge So Much

Hospitals rarely bill any of the three DOACs as a standalone pharmacy line item when the drug is given during an inpatient stay. Instead, Eliquis, Xarelto, and Pradaxa doses given while admitted are bundled into the Diagnosis-Related Group (DRG) payment Medicare pays the hospital for that admission, regardless of which specific DOAC was used. Private insurers negotiate their own bundled inpatient rates separately from any single drug's retail price. Uninsured patients face the hospital's chargemaster rate for a bundled stay, which can run several times what an outpatient 30-day supply of the same drug would cost at a retail pharmacy.

Medicare Part A stops paying for the DOAC the moment a patient is discharged, and coverage shifts entirely to Medicare Part D for the outpatient prescription. That transition is where the 2026 IRA Maximum Fair Price for Eliquis ($231/month) and Xarelto ($197/month) kicks in, along with standard Part D formulary tier cost-sharing for Pradaxa. Patients discharged on a new DOAC prescription without an active Part D plan often face sticker shock at the outpatient pharmacy because they assumed the inpatient DRG rate would carry over. Anyone leaving the hospital on Eliquis, Xarelto, or Pradaxa without Part D coverage should call 1-800-MEDICARE before the first fill.

Warfarin, the decades-old generic anticoagulant sold as Coumadin, remains the lowest-cost fallback across all three DOAC scenarios at roughly $4 to $15 per month, but it requires regular INR blood monitoring and has different food and drug interaction rules than any of the three DOACs. None of the three DOACs compared here is a biologic, so the biosimilar approval pathway that lowers costs for drugs like Humira or Stelara simply does not exist for apixaban, rivaroxaban, or dabigatran; cost reduction for these three drugs comes only through small-molecule generic competition, IRA negotiation, or manufacturer patient assistance. Patients who cannot afford any of the three should ask their prescriber whether warfarin is clinically appropriate rather than skipping doses or stopping anticoagulation without a plan, since interrupted anticoagulation carries meaningful stroke and clot risk.

Patient Assistance Programs

Bristol Myers Squibb, Janssen, and Boehringer Ingelheim each run a separate patient assistance program for their DOAC, and the income thresholds differ meaningfully across the three. If you have no insurance and a modest income, the cost of your DOAC may be $0 through the correct manufacturer program, but you must apply to the specific manufacturer of your prescribed drug; there is no single combined DOAC assistance program.

Medicare Part D

Medicare Part D treats these three DOACs very differently in 2026. Eliquis and Xarelto are subject to the IRA Maximum Fair Price of $231 and $197 per month respectively, applied at any network pharmacy regardless of which specific plan you carry. Pradaxa has no negotiated price; your out-of-pocket cost depends entirely on your Part D plan's formulary tier for brand Pradaxa versus generic dabigatran, and most plans place generic dabigatran on a much lower tier with a smaller copay than the two IRA-negotiated brands. All out-of-pocket spending on any of the three drugs counts toward the same 2026 Part D annual out-of-pocket cap of $2,100; once you hit that cap across all your Part D drugs combined, you pay $0 for the rest of the calendar year.

Extra Help (the Part D Low Income Subsidy) reduces cost-sharing further for Medicare beneficiaries with limited income and resources. In 2026, Extra Help enrollees pay $12.65 per fill for a brand-name drug like Eliquis, Xarelto, or brand Pradaxa, and a smaller copay for generic dabigatran or generic 2.5mg rivaroxaban. Extra Help is generally available to beneficiaries with income at or below 150% of the Federal Poverty Level. Apply through the Social Security Administration at 1-800-772-1213 or at ssa.gov, and mention which specific DOAC you take since eligibility rules for the manufacturer PAP on top of Extra Help vary by drug.

Common DOAC Comparison Billing Errors

All three DOACs are self-administered oral tablets billed through Part D or a commercial pharmacy benefit rather than Part B, so most billing problems appear on pharmacy claims or Explanation of Benefits statements rather than hospital bills. Watch for these issues:

• Pharmacy charges more than the $231 Eliquis or $197 Xarelto IRA Maximum Fair Price for a Medicare Part D fill in 2026, which violates federal law; ask your plan's member services to reprocess the claim.
• Generic dabigatran or generic 2.5mg rivaroxaban billed at the brand-name price instead of the generic tier.
• Manufacturer savings card applied for a patient who has Medicare or Medicaid, which is prohibited and can result in a claim clawback later.
• Step therapy denial requiring a warfarin trial without documenting that warfarin is clinically inappropriate or was already tried and failed.
• Wrong DOAC billed under the wrong NDC, for example Xarelto's code appearing on a claim when Eliquis was actually dispensed, which can trigger an incorrect copay or coverage denial.
• Charged the standard copay after you already hit the $2,100 Part D annual out-of-pocket cap for the year across all your combined Part D drugs.

Frequently Asked Questions